Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

SEER Cancer Statistics Review, 1975-2003

2006 • 11,387 citations

Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation

1997 • 4,191 citations

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

2003 • 2,642 citations

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

1999 • 2,565 citations

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

2005 • 2,457 citations

The RB and p53 pathways in cancer

2002 • 1,612 citations

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

2001 • 1,520 citations

Canonical Wnt Signaling in Differentiated Osteoblasts Controls Osteoclast Differentiation

2005 • 1,493 citations

The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma

2003 • 1,491 citations

To cycle or not to cycle: a critical decision in cancer

2001 • 1,429 citations

Multiple Myeloma

2004 • 1,219 citations

The molecular classification of multiple myeloma

2006 • 1,078 citations

Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases

2004 • 971 citations

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome

2007 • 894 citations

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

2006 • 890 citations

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

2000 • 868 citations

Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines

1999 • 850 citations

Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1

2003 • 843 citations

Multiple myeloma: evolving genetic events and host interactions

2002 • 815 citations

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

2002 • 812 citations

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

2002 • 759 citations

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

2003 • 721 citations

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

2005 • 689 citations

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

2005 • 687 citations

Evidence for the Secretion of an Osteoclast Stimulating Factor in Myeloma

1974 • 681 citations

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

2002 • 670 citations

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

1997 • 657 citations

Clinical and biologic implications of recurrent genomic aberrations in myeloma

2003 • 648 citations

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

2005 • 639 citations

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

2004 • 621 citations

Advances in biology of multiple myeloma: clinical applications

2004 • 606 citations

Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma

1999 • 590 citations

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

2005 • 588 citations

Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B

1996 • 582 citations

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341

2003 • 572 citations

Essential Role of β-Catenin in Postnatal Bone Acquisition

2005 • 570 citations

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

2001 • 562 citations

The t(4;14) Translocation in Myeloma Dysregulates Both FGFR3and a Novel Gene, MMSET, Resulting in IgH/MMSET Hybrid Transcripts

1998 • 555 citations

Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma

2005 • 554 citations

Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma

2000 • 547 citations

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

2003 • 538 citations

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications

2003 • 535 citations

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

2001 • 525 citations

Chromosome translocations in multiple myeloma

2001 • 481 citations

Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

2002 • 467 citations

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

2006 • 466 citations

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma

2006 • 464 citations

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

2006 • 431 citations

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

2002 • 431 citations

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

2006 • 429 citations

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

2006 • 428 citations

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

2001 • 420 citations

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

2001 • 419 citations

The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications

2001 • 398 citations

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

2006 • 398 citations

The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis

2007 • 397 citations

Hypodiploidy is a major prognostic factor in multiple myeloma

2001 • 394 citations

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma

1996 • 389 citations

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

2003 • 388 citations

Frequent Dysregulation of the c-maf Proto-Oncogene at 16q23 by Translocation to an Ig Locus in Multiple Myeloma

1998 • 388 citations

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

2001 • 385 citations

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

2004 • 365 citations

Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.

1992 • 363 citations

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

2006 • 361 citations

Genomic abnormalities in monoclonal gammopathy of undetermined significance

2002 • 351 citations

Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

2006 • 344 citations

Diverse karyotypic abnormalities of the c -myc locus associated with c -myc dysregulation and tumor progression in multiple myeloma

2000 • 344 citations

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2

2005 • 342 citations

Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)

2000 • 338 citations

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients

2002 • 331 citations

Wnt signalling in osteoblasts regulates expression of the receptor activator of NFκB ligand and inhibits osteoclastogenesis in vitro

2006 • 326 citations

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

2002 • 324 citations

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

2004 • 322 citations

Antimyeloma activity of heat shock protein-90 inhibition

2005 • 321 citations

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

2005 • 318 citations

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

2003 • 312 citations

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

2002 • 309 citations

Multiple myeloma bone disease: pathophysiology of osteoblast inhibition

2006 • 299 citations

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

2003 • 296 citations

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

2001 • 296 citations

Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines [see comments]

1996 • 296 citations

The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated**This work was supported by Grant AG-04875 from the National Institute on Aging.

2000 • 292 citations

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

2003 • 290 citations

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

2004 • 288 citations

Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells

2006 • 284 citations

Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.

2002 • 281 citations

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

2006 • 275 citations

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

2006 • 268 citations

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib

2005 • 264 citations

Heparanase Enhances Syndecan-1 Shedding

2007 • 260 citations

RANK ligand and osteoprotegerin in myeloma bone disease

2003 • 260 citations

A Crosstalk Between Myeloma Cells and Marrow Stromal Cells Stimulates Production of DKK1 and Interleukin-6: A Potential Role in the Development of Lytic Bone Disease and Tumor Progression in Multiple Myeloma

2005 • 258 citations

Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling

2007 • 249 citations

RANKL Expression Is Related to the Differentiation State of Human Osteoblasts

2003 • 239 citations

Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells

1996 • 230 citations

A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma

2006 • 229 citations

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

2003 • 229 citations

The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells

2003 • 226 citations

Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma

2001 • 224 citations

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

2003 • 220 citations

Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

2006 • 217 citations

Survival and Proliferation Factors of Normal and Malignant Plasma Cells

2003 • 216 citations

Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease

2001 • 214 citations

Monoclonal gammopathy of undetermined significance

2006 • 212 citations

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions

2006 • 208 citations

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

2007 • 206 citations

Cell responses to FGFR3 signalling: growth, differentiation and apoptosis

2004 • 204 citations

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma

2005 • 203 citations

Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity

2000 • 201 citations

CD40 ligand triggered interleukin-6 secretion in multiple myeloma

1995 • 198 citations

A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains anIGH/MMSET fusion transcript

2003 • 194 citations

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma

2006 • 193 citations

Soluble syndecan-1 promotes growth of myeloma tumors in vivo

2002 • 191 citations

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

2001 • 190 citations

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

2004 • 189 citations

Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease

2001 • 188 citations

Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique

2001 • 185 citations

Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells

2003 • 183 citations

Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation

2002 • 182 citations

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

2005 • 180 citations

Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity

2000 • 178 citations

Endothelial cells in the bone marrow of patients with multiple myeloma

2003 • 177 citations

Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior.

1994 • 177 citations

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

2002 • 176 citations

Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases

1998 • 170 citations

HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma

2006 • 170 citations

Focus on multiple myeloma

2004 • 169 citations

Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma

2006 • 168 citations

Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40–Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications

2005 • 166 citations

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma

2004 • 165 citations

Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple Myeloma

2005 • 165 citations

Pathogenesis of myeloma bone disease

2004 • 164 citations

Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma

2002 • 163 citations

The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone Marrow

1997 • 163 citations

Angiogenesis in multiple myeloma

2006 • 161 citations

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

2002 • 157 citations

Integrin-Mediated Drug Resistance in Multiple Myeloma

2000 • 155 citations

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

2006 • 148 citations

MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells

2005 • 148 citations

Effects of PS-341 on the Activity and Composition of Proteasomes in Multiple Myeloma Cells

2005 • 143 citations

Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.

2003 • 143 citations

Cbfa1 as a regulator of osteoblast differentiation and function

1999 • 142 citations

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

2006 • 142 citations

Identification of genes modulated in multiple myeloma using genetically identical twin samples

2003 • 141 citations

The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells

2006 • 140 citations

Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications

2004 • 134 citations

Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma

2005 • 133 citations

Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias

1993 • 131 citations

Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling

2005 • 131 citations

Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma

2003 • 130 citations

Cytotoxic activity of the maytansinoid immunoconjugate B-B4–DM1 against CD138+ multiple myeloma cells

2004 • 127 citations

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)

2006 • 120 citations

A clinically relevant SCID-hu in vivo model of human multiple myeloma

2005 • 116 citations

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-κB ligand (RANKL)

2004 • 115 citations

Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226.

1993 • 114 citations

Insertion of Excised IgH Switch Sequences Causes Overexpression of Cyclin D1 in a Myeloma Tumor Cell

1999 • 111 citations

Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid.

2000 • 110 citations

Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.

2003 • 106 citations

Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas

2007 • 106 citations

Didox (A Novel Ribonucleotide Reductase Inhibitor) Overcomes bcl-2 Mediated Radiation Resistance in Prostate Cancer Cell Line PC-3

2002 • 101 citations

Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases

2003 • 99 citations

Histone Deacetylase Inhibition Down-Regulates Cyclin D1 Transcription by Inhibiting Nuclear Factor-κB/p65 DNA Binding

2005 • 98 citations

Microarray Analysis of Epigenetic Silencing of Gene Expression in the KAS-6/1 Multiple Myeloma Cell Line

2004 • 98 citations

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies

2005 • 97 citations

Insulin-Like Growth Factor-1 Acts as a Chemoattractant Factor for 5T2 Multiple Myeloma Cells

1999 • 96 citations

Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma

2006 • 92 citations

Syndecan‐1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival

2004 • 90 citations

Potential Clinical Applications of the CXCR4 Antagonist Bicyclam AMD3100

2005 • 90 citations

Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib

2004 • 84 citations

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications

2006 • 81 citations

Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma

2005 • 74 citations

Bortezomib Inhibits Cell-Cell Adhesion and Cell Migration and Enhances Epidermal Growth Factor Receptor Inhibitor–Induced Cell Death in Squamous Cell Cancer

2007 • 71 citations

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation

2006 • 70 citations

Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)

2001 • 70 citations

Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma.

2006 • 66 citations

Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression

2006 • 61 citations

DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies

2004 • 61 citations

Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.

1999 • 61 citations

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341

2004 • 59 citations

Regulation of Cell Proliferation by Autocrine Motility Factor/Phosphoglucose Isomerase Signaling

2003 • 57 citations

Transforming growth factor-β increases interleukin-6 transcripts in osteoblasts

2000 • 45 citations

Cyclin Proteolysis as a Retinoid Cancer Prevention Mechanism

2001 • 43 citations

The Ubiquitin–Proteasome System and Cellular Proliferation and Regulation in Osteoblastic Cells

1998 • 40 citations

Post-Translational Modifications of Eukaryotic Initiation Factor-5A (eIF-5a) as a New Target for Anti-Cancer Therapy

1999 • 38 citations

New Potential Targets for Treating Myeloma Bone Disease

2006 • 38 citations

Ploidy status rarely changes in myeloma patients at disease progression

2005 • 33 citations

Small Molecule Inhibition of Proteasome and Aggresome Function Induces Synergistic Anti-Tumor Activity in Multiple Myeloma.

2005 • 30 citations

Chondroitin Synthase 1 Is a Key Molecule in Myeloma Cell-Osteoclast Interactions

2004 • 27 citations

Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies

2005 • 26 citations

Using Genomics to Identify High-Risk Myeloma after Autologous Stem Cell Transplantation

2006 • 23 citations

Promiscuous Mutations Frequently Activate the Non-Canonical NFkB Pathway in Multiple Myeloma (MM).

2006 • 3 citations